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Clinical Pacing Post-Conditioning During
Revascularization After AMIJohannes Waltenberger, MD,*y Marloes Gelissen, BS,*z Sebastiaan C. Bekkers, MD, PHD,*
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Maastricht, the Netherlands; Münster, Germany; Diegem, Belgium; and St. Paul, MinnesotaIntermittent dyssynchrony, induced by ventricular pacing, during early reperfusion reduces infarct size
in pre-clinical studies. We evaluated cardioprotection by pacing post-conditioning (PPC) in ST-segment
elevation myocardial infarction in a randomized, controlled, single-center, single-blinded, ﬁrst-in-man
study. Patients with ﬁrst ST-segment elevation myocardial infarction received either PPC plus
percutaneous coronary intervention (PCI) (n ¼ 30) or PCI (n ¼ 30). PPC consisted of 10 episodes of
30-s right ventricular pacing. Infarct size was measured as the area under the curve of creatine kinase
(CK) (primary endpoint) and by contrast-enhanced cardiac magnetic resonance. The CK area under
the curve was not signiﬁcantly different between study groups. Adjusted contrast-enhanced cardiac
magnetic resonance data showed w25% smaller infarct size in PPC þ PCI than in PCI patients after
4 days (p ¼ 0.01), 4 months (p ¼ 0.02), and 1 year of PCI (p ¼ 0.08). In PPC þ PCI, (uncomplicated)
ventricular ﬁbrillation (n ¼ 3) and paroxysmal atrial ﬁbrillation (n ¼ 4) were observed as opposed to 1
and 0 cases in PCI, respectively. We conclude PPC is feasible and may induce cardioprotection during
PCI treatment of ST-segment elevation myocardial infarction, but technical improvements are needed
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A B B R E V I A T I O N S
A N D A C R O N YM S
AF = atrial ﬁbrillation
CE-CMR = contrast-enhanced
cardiac magnetic resonance
CK = creatine kinase
IPoC = ischemic post-
conditioning
LV = left ventricular
PCI = percutaneous coronary
intervention
PPC = pacing post-conditioning
TIMI = Thrombolysis In
Myocardial Infarction
VF = ventricular ﬁbrillation
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621One of the most interesting and promising ways to
protect the heart during an ischemic attack is post-
conditioning through interventions in the early
reperfusion phase. Post-conditioning has been
proven to be effective in many studies and has the
potential to be applied in the clinic as it can be
performed at the time of reperfusion. Various trig-
gers may induce post-conditioning, such as repeated
coronary reocclusion in the early reperfusion phase
(ischemic post-conditioning [IPoC]). Also drugs
(cyclosporine-A) and remote ischemic conditioning can
exert cardioprotection (seeHausenloy andYellon (1) for
review).
We previously demonstrated that in rabbit and
pig hearts protection can also be achieved by brief
periods of ventricular pacing in the early reperfusion
phase (pacing post-conditioning [PPC]). PPC ap-
pears to act through a different trigger than IPoC
does, which presumably is related to mechanical
stimuli. The aim of the present study was to
determine whether the application of PPC during
primary percutaneous coronary intervention (PCI)
in STEMI can protect the human heart from
ischemia/reperfusion injury.
Trial. The PROTECT (Pacing to Protect Heart for
Damage From Blocked Heart Vessel and From Re-
opening Blocked Vessel[s]) study was a prospective,
single-center, randomized, single-blinded, controlled
ﬁrst-in-man trial. The study was performed in
accordance with the Declaration of Helsinki (revised
version, 2004) and with ISO (International Orga-
nization for Standardization) guidelines 14155-
1:2003 and 14155-2:203. In accordance with Dutch
law, the study protocol was approved by the ethics
committee of the Maastricht University Medical
Center. All subjects gave witnessed oral informed
consent before inclusion in the study (before PCI)
and an extended written informed consent 1 to 6
days after PCI.
We included men and women $18 years of age
who presented with their ﬁrst documented myo-
cardial infarction and were admitted to the hospital
1 to 6 h after symptom onset with clinical decision
for treatment with primary PCI.
We excluded patients with any of the following:
clinical or hemodynamic instability requiring me-
chanical or pharmacological circulatory support;
bradycardia (second- or third-degree atrioventric-
ular block) requiring antibradycardia pacing prior
to enrollment; tachycardia (>120 beats/min) at
the time of enrollment; permanent atrial ﬁbrilla-
tion (AF), history of ventricular ﬁbrillation (VF),
implanted pacemaker, implantable cardioverter-
deﬁbrillator or cardiac resynchronization therapydevice; previous PCI and/or coronary artery bypass
graft; stroke or cerebrovascular surgery (within 12
months); receiving thrombolytics upon clinical
presentation; mechanical tricuspid valve; and dia-
betes treated by peroxisome proliferator-activated
receptor agonists and/or ﬁbrates.
Dropout criteria include the following: reference
vessel diameter <3.0 mm at coronary angiography;
TIMI (Thrombolysis In Myocardial Infarction)
ﬂow grade $2; non–infarct-related coronary lesions
that cannot be left untreated during the follow-up
period (physician’s discretion).
Withdrawal criteria include the following: fail-
ure to position right ventricular pacing lead; atrial
ﬁbrillation at the time of PCI; intrinsic heart rate
>120 beats/min between the time of guidewire
advancement across the lesion (t0) and t0 þ 10
min, or at the time of ventricular pacing;
bradycardia (second- or third-degree
atrioventricular block) causing symptom-
atic hypotension or heart failure, requiring
antibradycardia pacing during PCI pro-
cedure; loss to follow-up; refusal of
testing; consent withdrawal; and in-
vestigator’s decision.
Pacing protocol. Patients randomized to
the PPC þ PCI group received a tempo-
rary pacing wire (Pacel bipolar pacing
catheter, St. Jude Medical, St. Paul,
Minnesota) via the femoral vein, posi-
tioned in the right ventricular apex and
connected to an external pacemaker
(Medtronic 5348, Medtronic Inc., Min-
neapolis, Minnesota). PPC started when
the guidewire crossed the lesion and
consisted of 10 cycles of 30 s pacing off
and 30 s pacing on. Pacing was performed in the
ventricular inhibited mode, 10 to 20 beats/min
above intrinsic sinus rhythm.
Infarct size assessment. The primary endpoint was
infarct size as assessed by plasma levels of creatine
kinase (CK). Blood samples were obtained at hos-
pital admission and after 3, 6, 9, 12, 24, 36, 48, 60,
and 72 h. Also lactate dehydrogenase was analyzed
and the area under the curve was determined. In
addition, infarct size was assessed by serial contrast-
enhanced cardiac magnetic resonance (CE-CMR),
which is currently the gold standard in infarct size
determination.
CMR imaging protocol. CMR was performed 4
days, 4 months, and 12 months after PCI. Left
ventricular (LV) function was assessed using
breath-hold electrocardiogram-gated steady-state
free-precession cine imaging in the cardiac short
Figure 1.
CPU ¼ ch
PCI ¼ per
Pts ¼ pat
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622axis and vertical and horizontal long axes.
Contrast-enhanced images were acquired 10 min
after intravenous administration of 0.2 mmol/kg
gadolinium-diethylenetriaminepentaacetic acid
(Magnevist, Schering, Germany) using single
breath-hold, 3-dimensional inversion recovery
gradient-echo sequence completely covering the
LV.
Image analysis. CE-CMR images were analyzed
using CAAS MRV software (version 3.0, Pie
Medical Imaging, Maastricht, the Netherlands)
blinded to clinical information. After tracing
endocardial and epicardial borders, infarct size
was assessed using a signal intensity threshold of
5 SD above the signal intensity of remote non-
infarcted myocardium in the same slice. Infarct
size was expressed as percent of LV mass and
included any central areas of hypoenhancement
within the area of hyperenhancement (microvas-
cular obstruction).
Analysis of arrhythmias. Immediately upon in-
clusion, the patients received a Holter monitor
(DR180þ, NorthEast Monitoring Inc., Maynard,
Massachusetts) for 24-h recording. Data were
analyzed using Holter LX Pro software (North-
East Monitoring). Arrhythmias evaluated by the
core laboratory were VF, ventricular tachycardia,Patient Flow From Initial Screening to Follow-Up
est pain unit; Excl ¼ exclude; F-up ¼ follow-up; Incl ¼ include;
cutaneous coronary intervention; PPC ¼ pacing post-conditioning;
ients.ventricular extrasystoles (discriminating among
nonsustained ventricular tachycardia and pairs and
single extrasystoles), and AF.
Power calculation and statistical analysis. Assuming
an effect of therapy on infarct size reduction of 40%
and a SD of infarct size within groups of 30%, a
group size of 25 patients was required to reach a
level of signiﬁcance of 0.05 with a power of 0.90.
Descriptive statistics for randomized groups were
generated and comparisons of baseline characteris-
tics were performed using Student t or chi-square
tests as appropriate. The analyses of differences
in infarct size and ventricular dimensions were
performed using linear models, taking into account
the repeated nature of these measurements. After
ﬁnding signiﬁcant interactions of the variables
treated artery, absolute ST-segment deviation, and
time from ﬁrst symptom with infarct size, as
measured by CE-CMR, data were adjusted for
these 3 variables using analysis of covariance. A
p value <0.05 was considered signiﬁcant.
Results. Patient ﬂow is depicted in Figure 1. In the
control group, 3 patients were withdrawn due to
unsuccessful PCI. In the therapy group, 2 patients
were withdrawn due to VF before pacing, 1 due to
AF before pacing, and 1 due to consent withdrawal.
One additional patient in the control group was
excluded from analysis because of a gross error in
estimating ischemia time (on the basis of clinical
information). Thus, following patient withdrawal
and exclusion, primary endpoint data was analyzed
from 52 patients.
Characteristics of the control and therapy groups
are presented in Table 1. Groups were generally
comparable, but on average, the therapy group had
longer time from symptom onset to hospital
admission and higher ST-segment deviations than
did the control group, whereas the latter had a
higher number of right coronary artery occlusions.
Figure 2 shows typical examples of CE-CMR
images obtained at 4 days, 4 months, and 1 year
after PCI in 1 patient of the control group and 1
from the therapy group. CE-CMR infarct size
showed a signiﬁcant correlation to the maximum
ST-segment deviation before PCI. The slope of the
regression line was smaller in the therapy group than
in the control group (Fig. 3A). Of note, the 5 largest
values for ST-segment deviation belonged to pa-
tients in the therapy group. In the subgroup of pa-
tients with right coronary artery occlusion, infarct
size determined by CE-CMR was signiﬁcantly
smaller in the therapy group than in the control
group (10.6  6.1% vs. 15.9  8.1%, p ¼ 0.04)
(Fig. 3B).
Table 1. Patient Characteristics
Control Therapy p Value
Patients 27 25
Age, yrs 60  10 60  11 0.80*
Male 19 (70) 17 (68) 0.85y
Diabetes mellitus 2 (7.4) 3 (12) 0.57y
Hypertension 9 (33) 12 (48) 0.28y
Hypercholesterolemia 3 (11) 3 (12) 0.92y
Smoking 15 (55) 15 (60) 0.75y
Time from ﬁrst symptoms to admission, h 2.0  0.9 2.4  1.2 0.16*
Time from ﬁrst symptoms to PCI, h 2.8  1.0 3.3  1.2 0.12*
Time from ﬁrst symptoms to
revascularization, h
3.2  1.0 3.7  1.2 0.07*
Treated coronary artery
RCA (prox/mid/dist) 20 (74) 16 (64) 0.31y
LAD (prox/mid/dist) 7 (26) 7 (28)
Other 0 (0) 2 (8)
Rentrop grade
Grade 0 3 (11) 3 (12) 0.43y
Grade 1 13 (48) 16 (64)
Grade 2 11 (41) 6 (24)
ST-segment deviation, mm 5.5  2.8 6.1  3.4 0.52*
Values are n, mean  SD, or n (%). *Determined by Student t test. yDetermined by chi-
square test.
dist ¼ distal; LAD ¼ left anterior descending; PCI ¼ percutaneous coronary intervention;
prox ¼ proximal; RCA ¼ right coronary artery.
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623To address interaction of treated artery, ST-
segment deviation and time from symptom onset
to hospital admission with infarct size, these vari-
ables were used as covariates to evaluate infarct
size. No statistically signiﬁcant difference was
found between the adjusted area under the curve of
CK in the control group and the therapy group,
the primary endpoint of this study (p ¼ 0.70)
(Table 2). However, infarct size as measured by
CE-CMR was 29% and 27% smaller in the ther-
apy group than in the control group at 4 days and
4 months, respectively (p ¼ 0.01) and still tended
to be smaller after 1 year (23%, p ¼ 0.08) (Table 2,
Fig. 4). LV ejection fraction tended to be higher in
the therapy group, especially at 4 days and 1 year
(Table 2).
Arrhythmias during and after reperfusion.During
the PCI procedure, 4 patients developed VF (3
in the therapy group) and 4 other patients AF
(all in the therapy group) (Table 3). In all cases,
VF could be immediately deﬁbrillated. VF in
the control patient occurred when the guidewire
passed the occlusion, VF in the therapy group
occurred in 1 patient before placing the guide-
wire and pacing lead, in 1 patient during posi-
tioning of the pacing lead, and in 1 patient
during pacing (applying the withdrawal rule that
rhythm should be <120 beats/min at time of
reperfusion and no history of VF). (Data from
the VF patient in the control group and 2 VF
patients in the therapy group were excluded for
analysis of all other parameters.) No signiﬁcantFigure 2. PPC-Induced Infarct Size Reduction Demonstrated by CE-
Short-axis delayed-enhancement cardiac magnetic resonance images a
with inferior wall myocardial infarction on the basis of a proximal right
control patient and 17%, 15%, and 13%, respectively, in the patient wh
cardiac magnetic resonance; PPC ¼ pacing post-conditioning.differences were found between the groups with
respect to single and multiple premature ven-
tricular capture beats.CMR
t baseline, 4-month follow-up, and 12-month follow-up of 2 patients
coronary artery occlusion. Infarct size was 26%, 19%, and 17% in the
o underwent right ventricular pacing. CE-CMR ¼ contrast-enhanced
AB
Figure 3. Infarct Size (CE-CMR) in Relation to ST-Segment
Deviation and Localization
Infarct size (% LV), determined using CE-CMR at 4 days after percutaneous
coronary intervention for the control (pink circles) and the therapy patients
(blue circles), in relation to (A) maximal ST-segment deviation and (B) treated
artery (bars represent mean  SE). CE-CMR ¼ contrast-enhanced cardiac
magnetic resonance; LV ¼ left ventricle.
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624Concept. This ﬁrst-in-man study to evaluate the
feasibility and efﬁcacy of PPC during acute
reperfusion of STEMI indicates the following:
1) the primary endpoint of the study (enzyme
release) was not met; 2) CE-CMR data de-
monstrate a smaller infarct size by PPC þ PCI
as compared to PCI alone at 4 days and 4
months after PCI; 3) PPC þ PCI is feasible, butadditional attention may be required to improve
safety. Therefore, the present study shows that
it would be worthwhile to investigate in more
detail whether PPC is a useful adjunct treatment
algorithm to attenuate reperfusion damage fol-
lowing STEMI and reperfusion.
The reduction in infarct size, as measured by the
CE-CMR data is in agreement with previous ob-
servations from experiments in rabbits and pigs,
where PPC reduced infarct size by 40% to 50%,
both acutely and chronically (2). The percent re-
duction observed in PROTECT (29% after 4 days
and 27% after 4 months) is in the same range as that
shown for IPoC in patients.
The reduction in infarct size by CE-CMR was
not paralleled by a signiﬁcant reduction in enzyme
release. The explanation for the mismatch be-
tween enzyme and CE-CMR analysis is currently
unclear and remains to be determined. CE-CMR
is the current gold standard for assessing infarct
size and can be used to detect structural abnor-
malities in the myocardium indicating low reﬂow
or no reﬂow. In contrast, although frequently used
in clinical practice, plasma enzyme levels are an
indirect reﬂection of infarct size, because the
circulating enzyme levels are dependent on the
rate of release, breakdown, and clearance, as well
as distribution between intravascular and extra-
vascular space.
In the present study, no direct stenting was
used. Rather, the PPC protocol was added to the
routine PCI procedure, which allowed, for example,
thrombosuction for establishing reperfusion. Also,
in order to achieve proper reperfusion and stent
positioning, a variable number of balloon inﬂations
(ranging from 1 to 8) were used, which may mimic
the repeated reocclusions used for achieving IPoC.
In the therapy group, 2 patients experienced VF
that was potentially related to the pacing therapy: 1
due to positioning of the pacing lead in the right
ventricle; and 1 during pacing. Moreover, 4 patients
in the PPC group developed atrial ﬁbrillation.
These ﬁndings indicate that ﬁnal implementation of
PPC in the clinic requires technical improvements
that warrant higher safety, such as better sensing
and inhibition functions and a dedicated, automated
pacing equipment.
The optimal pacing location relative to the in-
farct may be an important consideration in this
therapy as well. It may also be advisable to modify
PPC delivery as well as the PPC pacing algo-
rithm. In that respect, it is of interest that our
recent animal studies showed that pacing cycles as
short as 5 s may provide the same protection as
Table 2. Enzyme Release and Cardiac Function
Control Therapy Difference p Value
CK, AUC 68,840  8,816 (51,094 to 86,587) 65,772  7,952 (49,765 to 81,778) 3,069  8,001 (–13,037 to 19,174) 0.70
Infarct size, % LV
4 days 21.7  2.3 (17.0 to 26.4) 15.4  2.1 (11.3 to 19.6) 6.3  2.2 (1.9 to 10.7) 0.01
4 months 18.6  2.0 (14.5 to 22.7) 13.9  1.7 (10.4 to 17.4) 4.7  1.9 (0.9 to 8.5) 0.02
12 months 16.2  2.2 (11.7 to 20.6) 12.5  1.9 (8.7 to 16.3) 3.7  2.0 (–0.4 to 7.8) 0.08
LVEF, %
4 days 52.2  2.2 (47.8 to 56.7) 55.3  1.9 (51.4 to 59.2) –3.1  2.0 (–7.2 to 1.1) 0.14
4 months 53.5  2.0 (49.4 to 57.7) 53.7  1.8 (50.2 to 57.3) –0.2  1.9 (–4.0 to 3.6) 0.92
12 months 49.6  2.7 (44.2 to 55.0) 53.6  2.3 (49.0 to 58.2) –4.0  2.4 (–9.0 to 1.0) 0.11
Values are mean  SE (95% conﬁdence intervals) after adjustment for treated artery, time from ﬁrst symptom to admission, and ST-segment deviation as explained in
the methods. The p values are from adjusted linear regression models.
AUC ¼ area under the curve; CK ¼ creatine kinase; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction.
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625the 10  30 s algorithm used in the present study.
These short “trigger” times may relate to the
supposed mechanism of PPC. Animal studies
suggest that PPC is mediated by abnormal me-
chanical loading, induced by ventricular pacingFigure 4. Changes in Infarct Size During the Initial 12 Months
After Infarction
Infarct size (% LV) determined by CE-CMR for the control (pink
circles) and therapy (blue circles) patients at 4 days (n ¼ 48),
4 months (n ¼ 44), and 12 months after percutaneous coronary
intervention (n ¼ 41). Data represent adjusted mean  SE. Data
were adjusted for ST-segment deviation, time from symptom
onset to hospital admission, and affected coronary artery, as
explained in the methods. C ¼ control group; LAD ¼ left anterior
descending; LCX ¼ left circumﬂex; P ¼ therapy group; RCA ¼ right
coronary artery; other abbreviations as in Figures 2 and 3.(dyssynchrony). Through pathways not yet un-
raveled (but that do not include G-coupled pro-
teins, as is the case in IPoC) PPC leads to
activation of well-known protective molecules such
as phosphoinositide 3-kinase, mitochondrial ade-
nosine triphosphate–sensitive potassium channel,
and protein kinase C (2).
Compared with other protective strategies dur-
ing PCI, PPC may have advantages. IPoC requires
repeated occlusion of a stented coronary artery
segment during PCI. In PPC, no additional me-
chanical contact with the sensitive vessel is required.
Also, PPC lacks potential effects in other organs or
the circulation, as may occur by administration of
drugs, such as adenosine and cyclosporine. More-
over, the demonstration of cardioprotection by PPC
in patients also makes it worthwhile to search for
new molecular targets of the pathways involved in
this protection.Table 3. Occurrence of Arrhythmias During Treatment and in
the Early Post-Treatment Period (Secondary Endpoint: Safety)
Control Therapy p Value
PVC Single 774 (166, 877) 950 (260, 1,525) 0.52
PVC Pairs 61 (8, 59) 75 (11, 97) 0.57
Start to t0 0 (0, 0) 0 (0, 0) NA
NSVT t0 to t0 þ 1 h 2 (0, 3) 1 (0, 2.5) 0.60
> t0 þ 1 h 2.5 (1, 4.8) 5 (1.5, 8.0) 0.18
AF 0 4
VF 1 3
Values are median (interquartile range). The p values were calculated using
Mann-Whitney U test.
AF ¼ atrial ﬁbrillation; NA ¼ not available; NSVT ¼ nonsustained ventricular
tachycardias; PVCs ¼ premature ventricular capture beats; t0 ¼ time of
guidewire advancement through lesion; VF ¼ ventricular ﬁbrillation.
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626Conclusions
The PROTECT study missed its primary
endpoint of reduction in CK release. However, the
CE-CMR data indicate that PPC has the po-
tential to reduce infarct size; moreover, PPC is
feasible in the clinical setting. Development of
better pacing tools (automated switching and
better sensing integrated in PCI tools) may facil-
itate clinical implementation. Besides, betterpacing algorithms may be required to reduce
proarrhythmic properties. The results of this study
clearly require further corroboration in a larger
trial.
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